Imricor Launches Imricor Cardiovascular, Opening New U.S. Market for Radiation-Free Cardiac Catheterization

New protocol-driven documentation, native MIPS reporting, and remote therapeutic monitoring bring Fusion's PT, OT, and speech platform entirely into adult physical therapy, with one shared platform in each age, so increasing practices never outgrow their EHR.

Imricor Medical Systems, Inc. is pleased to announce the launch of Imricor Cardiovascular, a novel vertical which increases the interventional MR (iMR) market for Imricor alongside its electrophysiology and ablation business. Ensuing recent FDA clearances for NorthStar and the Vision-MR Diagnostic Catheter, Imricor Cardiovascular provides U.S. hospitals an opportunity to create early leadership in radiation-free cardiac catheterization by performing this technology in an iMR lab applying the superior imaging power of magnetic resonance (MR).

Imricor Cardiovascular is intended to support a novel model of care that is both clinically meaningful and operationally compelling for clinics. By substituting separate MR imaging and X-ray cath lab sessions with a single-session system in the iMR lab, hospitals deliver a more combined care experience for patients and families while contributing to per-patient procedural time savings of around 35% and freeing presenting X-ray cath lab capacity for other interventional technology.

For patients, the value of Imricor Cardiovascular is particularly evident in congenital and pediatric cardiac care, where children with complex heart circumstances face repeated procedures over many years. The possibility of cardiac catheterization directed by MR without exposure to ionizing radiation make a meaningful difference in children’s lives and chronic health. In these cases, being allows to answer key clinical questions in a single technology result in less anesthetics, less disruption for families, and more efficient application of hospital resources, while providing physicians with more detailed anatomical, tissue, and functional information while the procedure.

Greg Englehardt, Imricor’s VP of Global Sales, said: “With Imricor Cardiovascular, hospitals can pioneer radiation-free cardiac care, safeguard vulnerable patients, and arm care teams with MR imaging. By doing this can also put their programs at the leading edge of iMR-guided catheterization in the United States.”

Imricor’s CEO, Steve Wedan, added: “This launch marks an important step forward for both patients and hospitals. We believe better imaging has the power to change how cardiac procedures are performed, and it is especially meaningful to see this change begin with children who can benefit from fewer separate sessions and the elimination of radiation.”

Hospitals who want to lead in iMR-driven care are encouraged to contact Imricor to learn more about implementation, training, and program advancement. Patients and families interested in radiation-free heart procedures should ask their doctors or hospital whether Imricor’s iMR technology is available at their center, or when their hospital plans to offer it.

According to Towards Healthcare, the U.S. cardiac ablation market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.5 billion in 2026 to approximately USD 8.26 billion by 2035. The market is expanding at a CAGR of 14.19% between 2026 and 2035.Cardiac ablation is a negligibly invasive management for abnormal heart rhythms. Medical care providers applications this technology to find and manage abnormal tissue in heart. This can correct heart rhythm. Cardiac ablation is a minimally invasive technology that generally doesn’t needs a lengthy hospital stay. A cardiac ablation technology restore a normal heart rhythm when medications fail or aren’t an ideal option as of their adverse effects. This technology even be lifesaving in some cases.

About Imricor Medical Systems

Imricor Medical Systems is the first and only organization to bring products to the catheter ablation market that are commercially viable and safe iCMR products. Imricor is a innovator and leader in advancing MRI-compatible products for cardiac catheter ablation technology, and believes it is the first organization in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation sector. Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation technology using the Vision-MR ablation catheter performed. Imricor Medical Systems, Inc. is a leading developer of innovative MRI-compatible healthcare devices which used to carry out MRI-guided cardiac catheter ablation technology. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and medical care facilities around the world by growing the success rates and bringing down the overall expenses of cardiac catheter ablation technology

A recent report by Towards Healthcare highlights that the U.S. cardiac ablation market is growing as cardiac ablation offers patients with arrhythmias relief from symptoms, and results in an advancement in quality of life. Cardiac ablation is a minimally invasive technology that generally doesn’t needs a prolonged hospital stay. A cardiac ablation procedure restores a normal heart rhythm when medicines fail or aren’t a supreme option because of their adverse effects. Cardiac ablations manage most types of fast heart arrhythmias. They’re usally the first-line option when consumer have symptomatic and life-threatening arrhythmias.